Together with evidence that JAM-A loss in high-grade mammary tumor models promotes apoptosis [12], it is therefore timely and important to pursue deeper interrogation of JAM-A as a novel clinical target for preventing or treating early-stage HER2-positive ER-negative breast cancer. The gene discussed is F11R; the disease is breast cancer.